Home  /  Resource Library  /  ICU Admissions After CAR-T Therapy Likely to Due to CRS and Neurotoxicity

ICU Admissions After CAR-T Therapy Likely to Due to CRS and Neurotoxicity

Study examined most frequent adverse events requiring intensive care unit hospitalization among patients with relapsed diffuse large b-cell lymphoma treated with CAR T axicabtagene ciloleucel.